Toggle Offcanvas
...
 
Vedolizumab Tenders

Vedolizumab Tenders

View Vedolizumab tenders, RFPs and contracts. Bid on readily available Vedolizumab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Vedolizumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Vedolizumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Vedolizumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Vedolizumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

8 Live Notices for Vedolizumab Tenders

Showing 1 to 8

Medicines From The List C List Of Medicines
country Serbia
posting date10 Feb 2025
deadline14 Mar 2025
Medicines From The List C List Of Medicines
country Serbia
posting date08 Feb 2025
deadline14 Mar 2025
Delivery Of Program And Other Medications
country Poland
posting date31 Jan 2025
deadline10 Feb 2025
Supply of DAPTOMYCIN INJ 500 MG VIALS, VEDOLIZUMAB 300MG IV. INJ, (SOFOSBUVIR 400MG + VELPATASVIR 100MG) TABLET
country Oman
posting date15 Jan 2025
deadline10 Feb 2025
Conclusion Of A Non-Exclusive Discount Agreement According To § 130A Para. 8 Sgb V For The Active Ingredient Vedolizumab, Atc L04Aa33 For The Period July 1St, 2023 - June 30Th, 2025
country Germany
posting date27 May 2023
deadline05 May 2025
Conclusion Of A Non-Exclusive Discount Agreement According To § 130A Para. 8 Sgb V For The Active Substance Vedolizumab, Atc L04Aa33 For The Period 07/01/2023 - 06/30/2025
country Germany
posting date26 May 2023
deadline05 May 2025
Conclusion Of Non-Exclusive Discount Agreements According To § 130A Paragraph 8 Sgb V For The Active Ingredient Vedolizumab
country Germany
posting date18 May 2023
deadline09 May 2025
Conclusion Of Non-Exclusive Discount Agreements According To § 130A Paragraph 8 Sgb V For The Active Ingredient Vedolizumab
country Germany
posting date17 May 2023
deadline09 May 2025

Share Share this page